Last reviewed 2026-04-23 · How we verify

RPH-104

RPH-104 is a small molecule that targets the SGLT2 receptor.

RPH-104 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting SGLT2, RPH-104 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers (PHASE1)
• Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever (PHASE2)
• Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine (PHASE2)
• Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD) (PHASE3)
• Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome (PHASE2)
• Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis (PHASE2, PHASE3)
• Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis (PHASE3)
• Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.